Find your next paid study

Alliance for Clinical Trials in OncologyNCT07059884

~$10 – $750

Actual pay is set by the research site.

Grade 1 Endometrial Endometrioid CarcinomaEndometrial Intraepithelial NeoplasiaMetabolic Comorbidities

Combination Tirzepatide and Levonorgestrel Intrauterine Device Therapy for Endometrial Intraepithelial Neoplasia (EIN) and Grade 1 Endometrioid Endometrial Carcinoma: A Pilot Window-of-Opportunity Study

This single-arm study will evaluate the feasibility, safety, and preliminary efficacy of tirzepatide in combination with standard levonorgestrel intrauterine d…

Milton S. Hershey Medical CenterNCT07812636

~$150 – $3,000

Actual pay is set by the research site.

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-s…

Bladder CarcinomaUreter CarcinomaRenal Pelvis Carcinoma+14 more

Guardant Health, Inc.NCT05059444

~$10 – $1,050

Actual pay is set by the research site.

PROCPlatinum Resistant Ovarian CancerEndometrial Cancer

A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

HWK-016-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-016, a targeted antibody-drug conjugate (ADC) in adult participants…

Whitehawk Therapeutics, Inc.NCT07470853

Actual pay is set by the research site.

Solid Tumors (Phase 1)HNSCCEndometrial Cancer+4 more

First-in-Human, Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of MTX-531, a Dual EGFR/PI3K Inhibitor, as Monotherapy in Adults With Advanced Solid Tumors

This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors. The …

MEKanistic Therapeutics, Inc.NCT07874880

Actual pay is set by the research site.

Observational

Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101)

The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. Th…

Endometrial Cancer

~$10 – $1,050

Actual pay is set by the research site.

Natera, Inc.NCT07339384

Acceptability of Testing DNA Markers in Vaginal Fluid for the Detection of Endometrial Cancer

This study evaluates how women feel about using DNA from a vaginal fluid collection for early detection of endometrial cancer.

Endometrial Carcinoma

~$10 – $750

Actual pay is set by the research site.

Mayo ClinicNCT07527143

Ovarian CancerEndometrial CancerGerm Cell Tumor+2 more

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of XmAb541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dos…

Recurrent Endometrial Cancer

Actual pay is set by the research site.

Xencor, Inc.NCT06276491

Phase 2

Phase 2 Open-Label Trial Investigating the Efficacy and Safety of Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line Immunotherapy Maintenance

The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endo…

University of MiamiNCT07594015

~$75 – $2,000

Actual pay is set by the research site.

Observational

Life on the Go 3: A Randomized Controlled Trial of Automated, Personalized Physical Activity Intervention Using Wearable Devices to Improve Immune Function and Clinical Outcomes in Ovarian and Endometrial Cancer Patients

This clinical trial compares the effect of an automated personalized physical activity intervention supported by wearable technology to standard of care on phy…

Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian Carcinoma+10 more

~$10 – $1,125

Actual pay is set by the research site.

Phase 2

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in pa…

Endometrial Cancer

Faeth TherapeuticsNCT06463028

~$75 – $2,800

Actual pay is set by the research site.

Head and Neck Squamous Cell Carcinoma HNSCCNon-Small Cell Lung Cancer NSCLCEsophageal Cancer+6 more

A Phase 1 Open-Label Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of STRO-004 in Adults With Refractory/Recurrent Metastatic Solid Tumors

This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1…